ROCKVILLE, Md.--(BUSINESS WIRE)--Precision Biologics is pleased to announce the completion of accrual to
its Phase 2 study utilizing its novel monoclonal antibody Ensituximab (NPC-1C).
NPC-1C targets a unique member of the MUC family that is specific to
colorectal cancer with little reactivity to normal cells. Encouraging
overall survival (OS) data was observed in the initial dose escalation
phase in patients with chemotherapy refractory metastatic colorectal
cancer. Patients in the preliminary study had an OS of 10.4 months,
comparing favorably to the historical control for a similar population
of patients (5.0 months). These results led to the current,
statistically powered Phase 2 design of the study in 47 patients with
colorectal cancer with a primary endpoint to increase overall survival
after treatment with NPC-1C. Results of the Phase 2 study will be
presented by Philip M. Arlen, MD, President and CEO of Precision
Biologics at the Oxford Global 16th Annual Drug Summit and 3rd
Annual Discovery Chemistry and Drug Designs Conference held on June 8th-9th,
2015 in Berlin, Germany. The presentation will be made available
following the conference on the Precision Biologics website, www.Precision-Biologics.com.
In addition, an abstract associated with this study is now available in
the ASCO Proceedings for the 2015 Annual Meeting: J Clin Oncol 33, 2015
(suppl; abstr e14013) http://abstracts.asco.org/156/AbstView_156_148099.html
Founded in February 2012 and commencing business in late September 2012,
Precision Biologics, Inc. is a clinical stage biotechnology corporation
focused on developing therapeutic and diagnostic products for the early
detection and treatment of cancer. Precision Biologics is uniquely
positioned to create innovative therapeutics through the use of
proprietary cancer vaccines, several of which have demonstrated success
in human trials.
Know more here.